Learn about Brink Therapeutics as it raises $4 million to go beyond CRISPR with engineered recombinases in CAR T therapy.

We are thrilled to welcome Chris to our team at this exciting time for Design, as we advance our portfolio of GeneTAC ® small molecules toward key clinical milestones,” said Pratik Shah, Ph.D., ...

Researchers from the International Institute of Molecular and Cell Biology in Warsaw (IIMCB) have described a new mechanism ...

Wound care patients across the PAM Health network of hospitals and outpatient clinics will now have access to an innovative ...

NEWARK, CA / ACCESS Newswire / April 16, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of ...

As of Tuesday, April 15, iTeos Therapeutics, Inc.’s ITOS share price has surged by 7.59%, which has investors questioning if ...

Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in ...

Nektar Therapeutics’s NKTR share price has surged by 6.81%, which has investors questioning if this is right time to sell.

Protagonist Therapeutics is a discovery through late ... Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera ...

However, mRNA itself is an exceptionally unstable molecule. This does not affect the safety of the therapy but limits its ...

Two dose levels of a single-administration gene therapy were well-tolerated and led to functional improvements in ambulatory ...

ONCOTELIC THERAPEUTICS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS ...